Changchun GeneScience Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1948-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://english.ciac.cas.cn/
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Dose Escalation of GS1-144 Tablets and the Effects of Food on the Pharmacokinetics of GS1-144 in a Chinese Population
Phase 1
Completed
- Conditions
- Vasomotor System; LabileHealthy Volunteer
- Interventions
- Drug: GS1-144 tablet
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT06385158
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
A Bioequivalence Study of Two Different PEG-rhGH Preparations.
Phase 1
Completed
- Conditions
- Pediatric Growth Hormone Deficiency (PGHD)
- Interventions
- Drug: PEG-rhGH with new preparation (T)Drug: PEG-rhGH with present preparation (R)
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 87
- Registration Number
- NCT06331026
- Locations
- 🇨🇳
Chengdu Xinhua Hospital, Chengdu, Sichuan, China
Long-term Follow-up Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference
Active, not recruiting
- Conditions
- Infertility
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 158
- Registration Number
- NCT06321107
- Locations
- 🇨🇳
The Sixth Affiliated Hospital, Sun Yat-sen University Guangdong Gastrointestinal Hospital, Guangzhou, Guangdong, China
A Study to Assess Safety and Tolerability of GS1-144 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Adult Healthy VolunteersVasomotor Symptoms
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT06204250
- Locations
- 🇦🇺
Linear Clinical Research, Perth, Western Australia, Australia
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
Phase 2
Recruiting
- Conditions
- Systemic Sclerosis Associated Interstitial Lung DiseaseRheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD)Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
- Interventions
- Drug: GenSci048 placebo
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06189495
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
A Clinical Trail to Compare Pharmacokinetics of Two PEG-rhGH Injections With Different Preparations
Phase 1
Completed
- Conditions
- Pediatric Growth Hormone Deficiency (PGHD)
- Interventions
- Drug: PEG-rhGH with new preparationDrug: PEG-rhGH with present preparation
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06135168
- Locations
- 🇨🇳
Chengdu Xinhua Hospital affiliated to North Sichuan Medical College, Chengdu, Sichuan, China
A Clinical Trial to Compare Pharmacokinetics of Two Different PEG-rhGH Preparations
Phase 1
Completed
- Conditions
- Pediatric Growth Hormone Deficiency (PGHD)
- Interventions
- Drug: PEG-rhGH with new preparationDrug: PEG-rhGH with present preparation
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06135155
- Locations
- 🇨🇳
Chengdu Xinhua Hospital affiliated to North Sichuan Medical College, Chengdu, Sichuan, China
A Study for the Treatment of Dry Eye in Postmenopausal Women
Phase 2
Recruiting
- Conditions
- Postmenopausal Women With DED
- Interventions
- Drug: EG017 ointmentDrug: EG017 ointment placebo
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06133166
- Locations
- 🇨🇳
Xiamen Ophthalmology Center Affiliated to Xiamen University, Xiamen, Fujian, China
The Pharmacokinetic and Bioavailability of GenSci094 Before and After a Change in Manufacturing Site
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06095206
- Locations
- 🇨🇳
Chengdu Xinhua Hospital, affiliated with Sichuan North Medical College, Chengdu,, Sichuan, China
To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference
Phase 3
Completed
- Conditions
- Infertility
- Interventions
- Drug: Placebo GenSci094Biological: RecFSH / Follitropin alfa (Days 8 to hCG)Drug: Placebo RecFSH / follitropin alfa
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 176
- Registration Number
- NCT06091436
- Locations
- 🇨🇳
The Sixth Affiliated Hospital, Sun Yat-sen University Guangdong Gastrointestinal Hospital, Guangzhou, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath